Summary & Overview
HCPCS Q4242: Amniocyte plus, per 0.5 cc
HCPCS Level II code Q4242 designates a unit of Amniocyte plus, per 0.5 cc, a biologic product used in regenerative medicine and wound-care applications. This code captures the supply or administration of a specific volume of an amniotic-derived product and matters nationally because biologic therapies continue to grow in utilization across outpatient and ambulatory care settings, influencing billing practices and coverage determinations.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare and Medicare. Readers will find a concise overview of what Q4242 represents clinically and operationally, plus the typical sites of service where the product is used. The publication outlines benchmarks and payer coverage considerations, highlights policy and coding updates relevant to HCPCS Level II biologic supplies, and situates the code within clinical workflows for regenerative and wound-care services.
The report provides practical billing context — unit definition, common service lines, and where to expect use of this code — and identifies areas where payers commonly set prior authorization or documentation requirements. Data not available in the input is clearly noted where applicable.
Billing Code Overview
HCPCS Level II code Q4242 represents Amniocyte plus, per 0.5 cc, a biologic product preparation derived from amniotic fluid or membrane components used in clinical settings for regenerative or wound care applications. The service type is biologic product administration / supply, reflecting a unit-based billing for a specific volume of the amniocyte plus preparation.
Typical site of service for HCPCS Level II code Q4242 is outpatient clinic or ambulatory care settings, including specialty clinics that perform regenerative medicine procedures or wound care. Hospital outpatient departments and physician offices are also common sites when biologic wound-care products or regenerative injections are administered or supplied to patients.
Clinical & Coding Specifications
Clinical Context
A patient with a chronic, nonhealing musculoskeletal or soft-tissue wound (for example, diabetic foot ulcer, chronic tendonitis, or joint surface cartilage loss) presents to an outpatient orthopedic or wound-care clinic. After evaluation, the clinician determines that an allogeneic, cryopreserved amniotic-derived biologic (Q4242 — Amniocyte plus, per 0.5 cc) is appropriate to augment local tissue healing. The workflow includes documentation of the wound or degenerative condition, informed consent for use of an amniotic tissue injectable or implant, measurement of the treatment volume, and ordering of Q4242 by the treating provider. In a clinic visit or minor procedure room, the provider prepares the wound bed or injection site using standard sterile technique, thaws/reconstitutes the product per manufacturer instructions, and administers the indicated volume (billing units by 0.5 cc) as an injectable or implanted adjunct. Immediate post-procedure monitoring for an allergic or inflammatory reaction occurs in the clinic for the typical observation period. Follow-up visits document wound progress, additional applications if needed, and any complications. Typical sites of service are outpatient clinic, ambulatory surgical center, or physician office procedural room. Typical providers include orthopedic surgeons, podiatrists, plastic surgeons, wound care specialists, and interventional pain specialists. Common patient scenarios include diabetic lower-extremity ulcers, superficial tendon or ligament partial-thickness injuries requiring biologic adjuncts, and degenerative joint focal defects treated with adjunctive amniotic tissue (off-label uses vary by practice).
Coding Specifications
| Modifier | Description | When to Use |
|---|